Drug Trial Radar · NCT07609914
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
May 28, 2026
Primary completion
Jun 7, 2028
Study completion Jun 7, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.
Conditions
- Acute Treatment of Migraine
Interventions
RimegepantDrug
Rimegepant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallTime frame: Up to 6 months
- Incidence of LFT elevations, AST >3x ULN, alanine aminotransferase ALT >3x ULN, and total bilirubin >2x ULN on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallTime frame: Up to 6 months
Locations
38 sites in 3 countries. Site status is shown where the registry gives one.
Hope Clinical Research
Canoga Park, California · Recruiting
Neuro-Pain Research Center
Fresno, California · Recruiting
Clinical Research Institute
Los Angeles, California · Recruiting
Neurology Offices of South Florida
Boca Raton, Florida · Recruiting
AppleMedical Research Group, Inc.
Miami, Florida · Recruiting
Brainstorm Research
Miami, Florida · Recruiting
Clinical Neuroscience Solutions
Orlando, Florida · Recruiting
Conquest Research-Winter Park
Winter Park, Florida · Recruiting
Cedar Crosse Research Center
Chicago, Illinois · Recruiting
Josephson Wallack Munshower Neurology
Indianapolis, Indiana · Recruiting
Collective Medical Research
Overland Park, Kansas · Recruiting
New England Regional Headache Center
Worcester, Massachusetts · Recruiting
Michigan Headache & Neurological Institute
Ann Arbor, Michigan · Recruiting
Minneapolis Clinic of Neurology - Burnsville Office
Burnsville, Minnesota · Recruiting
Proven Endpoints, LLC
Ridgeland, Mississippi · Recruiting
StudyMetrix Research
City of Saint Peters, Missouri · Recruiting
Papillion Research Center / Avacare Clinical Research Network
Papillion, Nebraska · Not yet recruiting
Alliance Clinical Research Las Vegas (Excel Clinical Research)
Las Vegas, Nevada · Recruiting
M3 Wake Research - Las Vegas Rainbow
Las Vegas, Nevada · Recruiting
Upstate Clinical Research Associates, LLC
Williamsville, New York · Recruiting
Headache Wellness Center
Greensboro, North Carolina · Recruiting
Abington Neurological Associates
Abington, Pennsylvania · Not yet recruiting
FutureSearch Trials of Neurology
Austin, Texas · Recruiting
FutureSearch Trials of Dallas
Dallas, Texas · Recruiting
Red Star Research, LLC
Lake Jackson, Texas · Recruiting
VIP Trials
San Antonio, Texas · Not yet recruiting
Highland Clinical Research
Salt Lake City, Utah · Not yet recruiting
Medstar Health - Department of Neurology
McLean, Virginia · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Xianyang Hospital of Yan'an University
Xianyang, Shaanxi, China · Not yet recruiting
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Not yet recruiting
Hillel Yaffe Medical Center
Hadera, Israel · Recruiting
Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Rabin Medical Center
Petah Tikva, Central District, Israel · Not yet recruiting
Sheba Medical Center
Ramat Gan, Central District, Israel · Recruiting
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.